Skip to main content
. Author manuscript; available in PMC: 2022 Oct 25.
Published in final edited form as: Invest New Drugs. 2018 Aug 31;37(2):307–314. doi: 10.1007/s10637-018-0662-1

Table 4.

Tumor Responses

Overall (N=27) Cohort I (N=15) Cohort II (N=12)

Best Response
 Partial Response 2 (7.4%) 0 2 (16.7%)
 Stable Disease 10 (37%) 9 (60%) 1 (8.3%)
 Progressive Disease 11 (40.7%) 6 (40%) 5 (41.7%)
 Too Early to Assess* 4 (14.8%) 0 4 (33.3%)
*

One patient discontinued due to adverse events, three refused further participation